ASSOCIATION OF CLINICAL RESEARCH PROFESSIONALS (ACRP) CERTIFIED PROFESSIONAL PRACTICE EXAM (SAMPLE)

STUDY GUIDE



SAMPLE STUDY GUIDE WITH LIMITED QUESTIONS

VISIT US ONLINE FOR THE FULL VERSION STUDY GUIDE

https://acrp-cp.examzify.com

Copyright © 2026 by Examzify - A Kaluba Technologies Inc. product.

ALL RIGHTS RESERVED.

No part of this book may be reproduced or transferred in any form or by any means, graphic, electronic, or mechanical, including photocopying, recording, web distribution, taping, or by any information storage retrieval system, without the written permission of the author.

Notice: Examzify makes every reasonable effort to obtain accurate, complete, and timely information about this product from reliable sources.

SAMPLE

Table of Contents

Copyright 1

Table of Contents 2

Introduction 3

How to Use This Guide 4

Questions 5

Answers 8

Explanations 10

Next Steps 16

SAMPLE

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- Practice answering questions under realistic conditions,
- Improve accuracy and speed,
- Review explanations to strengthen weak areas, and
- Approach the exam with greater confidence.

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

SAMPLE

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here's how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don't just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There's no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

SAMPLE

Questions

SAMPLE

1. What are expected adverse events (AEs) in clinical trials?

A. Unpredictable and severe side effects

B. Events inconsistent with patient histories

C. Events consistent with prior trials

D. Minor and temporary side effects

2. What action should be taken if persistent issues of noncompliance are detected during monitoring?

A. Allow the investigator some time to improve

B. Conduct a site visit to discuss the issues

C. Immediately implement corrective actions and inform the regulatory authority

D. Only inform the sponsor to take action

3. What must be conducted in conjunction with treatment to accurately estimate its risks and benefits?

A. Statistical analysis

B. Market research

C. Patient interviews

D. Ethical reviews

4. What does ICH stand for in clinical research guidelines?

A. International Council on Health

B. International Conference on Harmonisation

C. Integrated Clinical Healthcare

D. International Consortium of Hospitals

5. Are changes to an Investigator's Brochure (IB) required to be submitted to the IRB/IEC?

A. Yes, all changes must be submitted

B. No, changes are not required

C. Only specific safety language changes must be submitted

D. Changes only need submission if critical

SAMPLE

6. Which document provides prior clinical and nonclinical results of investigational products (IP) to the investigator?

A. Clinical trial agreement

B. Investigator's brochure

C. Study protocol

D. Ethics committee report

7. Should any changes to safety language in an Investigator's Brochure be submitted to the IRB/IEC?

A. Yes, all changes need to be submitted

B. No, changes are not necessary

C. Only significant changes need to be submitted

D. Only if the IRB requests it

8. What is one of the characteristics that must be specified in an estimand?

A. The control treatment

B. The population to be studied

C. The statistical software used

D. The study funding sources

9. Phase IV trials typically require which of the following?

A. Fewer subjects than Phase III

B. More subjects and data collection requirements

C. Only one comparator

D. No additional data collection

10. Where should a research subject's responsibilities for study participation be outlined?

A. Investigator's manual

B. Informed Consent Form (ICF)

C. Eligibility screening checklist

D. Clinical trial agreement

SAMPLE

Answers

SAMPLE

1. C
2. C
3. A
4. B
5. C
6. B
7. A
8. B
9. B
10. B

SAMPLE

Explanations

SAMPLE

1. What are expected adverse events (AEs) in clinical trials?

A. Unpredictable and severe side effects

B. Events inconsistent with patient histories

C. Events consistent with prior trials

D. Minor and temporary side effects

Expected adverse events (AEs) in clinical trials refer to events that have been previously observed and documented in prior studies or research related to a specific treatment or intervention. These events are anticipated based on existing data about the drug or device being tested, which helps researchers prepare for monitoring and managing these events during the trial. Identifying AEs that have been encountered in prior studies allows clinical trial teams to inform participants about possible risks and to develop strategies for monitoring patient safety effectively. Furthermore, expected AEs play a crucial role in risk assessment and benefit analysis during the design of the clinical trial, helping ensure that the potential harms are weighed against the anticipated benefits of the intervention. In contrast, unpredictable and severe side effects or events inconsistent with patient histories would not be classified as expected adverse events, as they deviate from what has been previously documented. Minor and temporary side effects may not always qualify as adverse events depending on their severity and impact on the patients' well-being. Hence, only those AEs that are consistent with prior trials provide a reliable framework for understanding possible outcomes during ongoing research.

2. What action should be taken if persistent issues of noncompliance are detected during monitoring?

A. Allow the investigator some time to improve

B. Conduct a site visit to discuss the issues

C. Immediately implement corrective actions and inform the regulatory authority

D. Only inform the sponsor to take action

When persistent issues of noncompliance are detected during monitoring, the most appropriate action is to immediately implement corrective actions and inform the regulatory authority. Addressing noncompliance promptly is essential to ensure participant safety, data integrity, and adherence to regulatory standards. Immediate corrective actions help to mitigate any potential risks associated with the noncompliance and demonstrate a proactive approach to regulatory adherence. Additionally, informing the regulatory authority is crucial as it maintains transparency and allows for oversight of the research process. Regulatory agencies require such notification to ensure that appropriate steps are taken to address any deficiencies and to potentially provide guidance on further actions that may be required. By not just relying on the investigator to improve on their own or limiting communication to the sponsor, the correct response prioritizes compliance and safety in the research environment, which is paramount in clinical trials.

SAMPLE

3. What must be conducted in conjunction with treatment to accurately estimate its risks and benefits?

A. Statistical analysis

B. Market research

C. Patient interviews

D. Ethical reviews

Statistical analysis is essential to accurately estimate the risks and benefits of a treatment because it provides a systematic and quantitative method to evaluate data gathered during clinical studies. By applying statistical methods, researchers can determine the significance of their findings, assess the likelihood of outcomes, and understand variations in responses among different populations. Statistical analysis allows for the comparison of treatment effects against control groups, and it can help in estimating confidence intervals and p-values that indicate the reliability of the results. This robust approach is crucial in drawing valid conclusions about the efficacy and safety of treatments, ultimately guiding clinical decisions and regulatory approvals. Other options, while valuable in different aspects, do not specifically provide a quantitative assessment of risks and benefits. Market research focuses on understanding patient preferences and treatment demand. Patient interviews can gather qualitative insights but lack the statistical rigor required for comprehensive risk-benefit analysis. Ethical reviews are imperative for ensuring the moral integrity of studies, but they do not inherently quantify risks and benefits. Therefore, the emphasis on statistical analysis is vital in this context to ensure that informed decisions regarding treatment can be made based on empirical evidence.

4. What does ICH stand for in clinical research guidelines?

A. International Council on Health

B. International Conference on Harmonisation

C. Integrated Clinical Healthcare

D. International Consortium of Hospitals

The correct answer refers to the International Conference on Harmonisation. This organization plays a vital role in the development of guidelines that promote consistency, efficiency, and quality in clinical research across different regions, particularly between Europe, Japan, and the United States. The International Conference on Harmonisation is important because it provides a platform for regulatory authorities and industry representatives to collaborate and define standards that enhance the safety and efficacy of pharmaceuticals. By harmonizing the standards, it seeks to ensure that clinical trials are conducted under the same rigorous conditions, regardless of the location, which is crucial for the global nature of clinical research. In contrast, the other options do not accurately reflect the organization formed for developing these guidelines. For example, "International Council on Health" and "Integrated Clinical Healthcare" lack specific ties to the harmonization of clinical practices across countries, while "International Consortium of Hospitals" does not focus on research guidelines but rather on hospital practices.

SAMPLE

5. Are changes to an Investigator's Brochure (IB) required to be submitted to the IRB/IEC?

A. Yes, all changes must be submitted

B. No, changes are not required

C. Only specific safety language changes must be submitted

D. Changes only need submission if critical

When deciding whether to submit Investigator's Brochure updates to the IRB/IEC, focus on how the change could affect subject safety. The IB is a living document that informs both investigators and participants about risks and how they're managed. Updates that alter the way safety is described or the risk profile—such as new adverse events, new safety findings, or changes to risk statements—should be reviewed and submitted to the IRB/IEC because they could influence risk assessment and informed consent. That's why the best choice is that only specific safety language changes must be submitted. Editorial or non-safety edits that don't change the risk information typically don't require IRB submission. If the change affects how risks are communicated or understood, it warrants IRB/IEC review; otherwise, it does not.

6. Which document provides prior clinical and nonclinical results of investigational products (IP) to the investigator?

A. Clinical trial agreement

B. Investigator's brochure

C. Study protocol

D. Ethics committee report

The Investigator's Brochure is a comprehensive document that provides critical information about an investigational product (IP). It is designed to inform the investigator and healthcare professionals involved in the clinical trial about the prior clinical and nonclinical results associated with the IP. This document contains essential data such as pharmacology, toxicology, and previous study outcomes that could affect the safety and efficacy evaluation of the product. The information presented in the Investigator's Brochure is crucial for enabling investigators to understand the background of the investigational product, assess the risk-benefit profile, and make informed decisions regarding participant safety and dosage during the trial. This foundation of knowledge is essential for the ethical conduct of clinical research, ensuring that investigators are well-equipped with relevant background information before participating in a study. In contrast, other options like the Clinical Trial Agreement relate more to the legal and operational aspects of conducting a trial, while the Study Protocol outlines the design and methodology of the study without providing prior results. An Ethics Committee Report typically focuses on the ethical considerations of a specific study rather than on providing historical data about the investigational product itself.

SAMPLE

7. Should any changes to safety language in an Investigator's Brochure be submitted to the IRB/IEC?

A. Yes, all changes need to be submitted

B. No, changes are not necessary

C. Only significant changes need to be submitted

D. Only if the IRB requests it

Submitting all changes to safety language in an Investigator's Brochure to the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) is essential for maintaining the integrity and safety of the research protocol. The IRB/IEC plays a crucial role in safeguarding the rights and welfare of participants involved in a clinical trial. As the Investigator's Brochure serves as a comprehensive resource regarding the investigational product, including its safety profile, any modifications to the safety language could indicate new risks or the need for updates on risk management strategies. The rationale behind this requirement is that any changes, no matter how minor they may seem, could have implications for participant safety or the ethical considerations of the study. By ensuring that all updates are reviewed by the IRB/IEC, researchers uphold ethical standards and transparency, allowing the board to reassess the risk-benefit balance of the study in light of the new information. This accountability ensures that informed consent is based on the most current and comprehensive understanding of the study's risks. In summary, submitting all changes to safety language ensures ongoing oversight and participant protection throughout the trial, aligning with regulatory requirements and best practices in clinical research.

8. What is one of the characteristics that must be specified in an estimand?

A. The control treatment

B. The population to be studied

C. The statistical software used

D. The study funding sources

One of the essential characteristics that must be specified in an estimand is the population to be studied. The estimand framework aims to clearly define the treatment effect of interest in a clinical trial or observational study. Specifying the target population is crucial because it outlines who the findings will apply to, ensuring that the analysis reflects the intended group of subjects. This facilitates the interpretation of results and their generalizability, as different populations may respond differently to treatments. In contrast, while the control treatment, statistical software, and study funding sources are important elements in the overall research design and methodology, they are not intrinsic characteristics of the estimand itself. The estimand's focus is solely on characterizing the treatment effect, which inherently requires a clear definition of the population that will be affected by the treatment being studied.

SAMPLE

9. Phase IV trials typically require which of the following?

A. Fewer subjects than Phase III

B. More subjects and data collection requirements

C. Only one comparator

D. No additional data collection

Phase IV trials, also known as post-marketing studies, are critical for monitoring the long-term effects and efficacy of a drug or therapy after it has received regulatory approval. These trials often involve a larger population than Phase III trials to gather extensive safety data and assess how the treatment performs in diverse, real-world scenarios. The greater number of subjects allows researchers to identify rare side effects and evaluate the drug's effectiveness across various demographics and varying health conditions. In addition, the data collection requirements in Phase IV trials are generally more comprehensive, including information on adverse events, patient-reported outcomes, and comparative effectiveness, as they seek to gather data that can inform ongoing clinical use and guide future prescribing practices. This robust design contrasts with some of the other phases, where the primary goal is typically to establish safety and efficacy under controlled conditions. Hence, the need for more subjects and rigorous data collection requirements in Phase IV trials is aligned with their objective of ensuring the ongoing safety and efficacy of the drug in the broader population after its approval.

10. Where should a research subject's responsibilities for study participation be outlined?

A. Investigator's manual

B. Informed Consent Form (ICF)

C. Eligibility screening checklist

D. Clinical trial agreement

The responsibilities of a research subject for study participation should be clearly outlined in the Informed Consent Form (ICF). The ICF is a critical document that ensures potential participants are fully informed about the study, including what is expected of them, the procedures involved, and any risks associated with participation. It serves not only to inform participants but also to protect their rights by ensuring they understand their role in the research. By detailing the subject's responsibilities, the ICF helps ensure that participants know what they need to do to contribute effectively to the research, such as attending visits, following protocols, and reporting any side effects. This clarity is essential for ethical research and compliance with regulatory standards. The ICF is signed by the participant, indicating their understanding and agreement to these outlined responsibilities. While the investigator's manual may contain relevant information for researchers about the study design and protocols, it is not meant for subjects. The eligibility screening checklist is focused on determining if individuals qualify to participate in the research, and the clinical trial agreement is a legal document governing the relationship between sponsors and researchers, without detailing participant responsibilities. Therefore, the ICF is the appropriate document for outlining the responsibilities of research subjects.

SAMPLE

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

https://acrp-cp.examzify.com

We wish you the very best on your exam journey. You've got this!

SAMPLE